Stockscreener 앱 받기
4.01
3.89%
0.15
전일 마감가:
$3.86
열려 있는:
$3.96
하루 거래량:
3,672
Relative Volume:
0.03
시가총액:
$9.48M
수익:
$9.26M
순이익/손실:
$-941.60K
주가수익비율:
-55.69
EPS:
-0.072
순현금흐름:
$-2.65M
1주 성능:
+1.52%
1개월 성능:
-2.43%
6개월 성능:
-32.38%
1년 성능:
+9.83%
1일 변동 폭
$3.91
$4.0858
1주일 범위
$3.84
$4.14
52주 변동 폭
$2.0068
$15.60
Bionexus Gene Lab Corp Stock (BGLC) Company Profile
명칭
Bionexus Gene Lab Corp
전화
1-307-241-6898
주소
10-2 TOWER B, VERTICAL BUSINESS SUITE,, KUALA LUMPUR
BGLC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BGLC
BioNexus Gene Lab Corp Common stock
|
0.343 | 201.51M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
3.39 | 4.30B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.92 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.84 | 340.50M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
7.50 | 314.36M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
47.57 | 0 | 0 | 0 | 0 | 0.00 |
Bionexus Gene Lab Corp 주식(BGLC)의 최신 뉴스
BioNexus Gene Lab stockholders back governance and incentive plan - MSN
Downgrade Watch: Can BioNexus Gene Lab Corp stock resist market sell offsShort Setup & Technical Pattern Alert System - moha.gov.vn
BioNexus Gene Lab Stockholders Back Governance and Incentive Plan - The Globe and Mail
BioNexus Gene Lab shareholders approve board, equity plan, and auditor at annual meeting - Investing.com Nigeria
BioNexus Gene Lab shareholders approve board, equity plan, and auditor at annual meeting By Investing.com - Investing.com South Africa
How supply chain issues affect BioNexus Gene Lab Corp. stockMarket Insider Reports & Capitalize On Fast Trends - bollywoodhelpline.com
BioNexus Gene Lab (NASDAQ:BGLC) Shares Down 0.2% – Should You Sell? - Defense World
BioNexus Gene Lab Shares Surge on Strategic MRD Testing Partnership - MSN
BioNexus Chemrex leadership resignations prompt governance review - The Globe and Mail
Bionexus Gene Lab CorpMatthew L. Barsing appointed as chairman of Chemrex boardSEC filing - marketscreener.com
BioNexus Gene Lab Corp Evaluates CDMO Expansion - TradingView — Track All Markets
How BioNexus Gene Lab Corp. stock reacts to job market dataJuly 2025 Setups & AI Powered Buy and Sell Recommendations - DonanımHaber
Inflation Data: Is BioNexus Gene Lab Corp. stock attractive after correctionQuarterly Portfolio Review & Daily Growth Stock Tips - DonanımHaber
What margin trends mean for BioNexus Gene Lab Corp. stockPortfolio Value Summary & Real-Time Volume Spike Alerts - DonanımHaber
Will BioNexus Gene Lab Corp. stock gain from lower inflation2025 Trade Ideas & Expert Approved Trade Ideas - DonanımHaber
Is BioNexus Gene Lab Corp. stock attractive after correction2025 Key Highlights & Growth Focused Entry Reports - DonanımHaber
Can BioNexus Gene Lab Corp. stock maintain growth trajectory2025 Market WrapUp & Stepwise Trade Execution Plans - Улправда
Bionexus Gene Lab completes investment in Fidelion Diagnostics - MSN
Analysis Recap: How BioNexus Gene Lab Corp stock valuations compare to rivalsStop Loss & Target Return Focused Stock Picks - moha.gov.vn
BioNexus Gene Lab stock soars after strategic MRD testing agreements By Investing.com - Investing.com Nigeria
Is BioNexus Gene Lab Corp. stock safe for conservative investorsWeekly Profit Summary & Stepwise Trade Execution Plans - Newser
12 Industrials Stocks Moving In Thursday's Pre-Market Session - Benzinga
A Look at BioNexus Gene Lab Corp (BGLC) Shares in the Recent Past Indicates Growth - setenews.com
Blue Gold Sets $15 Million Gold Trading Facility - marketscreener.com
Bionexus Gene Lab completes strategic investment in Fidelion Diagnostics, secures 15% equity stake in global AI Oncologic platform - MarketScreener
BioNexus Gene Lab completes strategic deal with Fidelion Diagnostics - Investing.com
BioNexus Gene Lab completes strategic deal with Fidelion Diagnostics By Investing.com - Investing.com South Africa
BioNexus Gene Lab Corp. Completes Strategic Transaction with Fidelion Diagnostics, Securing Exclusive Rights for VitaGuard™ in Southeast Asia - Quiver Quantitative
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard - marketscreener.com
BioNexus Gene Lab (NASDAQ: BGLC) acquires 15% Fidelion stake, VitaGuard ASEAN rights - Stock Titan
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™ - The Manila Times
BioNexus Gene Lab secures $500 million equity purchase agreement By Investing.com - Investing.com Nigeria
BioNexus Gene Lab stock falls after securing $500M equity facility - Investing.com Nigeria
BioNexus Gene Lab stock falls after securing $500M equity facility By Investing.com - Investing.com South Africa
BioNexus Gene Lab Shares Jump After Securing $500 Million Equity Facility - MSN
Bionexus Gene Lab secures $500M equity facility from ARC Group - TipRanks
BioNexus Gene Lab (BGLC) Stock Analysis Report | Financials & Insights - Benzinga
BioNexus Gene Lab secures $500 million equity purchase agreement - Investing.com
Bionexus Gene Lab Corp enters $500 million equity purchase agreement - marketscreener.com
BioNexus Gene Lab stock climbs after securing $500 million equity facility - Investing.com UK
BioNexus Gene Lab stock climbs after securing $500 million equity facility By Investing.com - Investing.com India
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization - The Manila Times
BioNexus Gene Lab (Nasdaq: BGLC) lines up $500M ARC equity facility for MRD, CDMO push - Stock Titan
Bionexus Gene Lab, Fidelion Diagnostics execute license for VitaGuard platform - TipRanks
Bionexus Gene Lab Corp to pay $2 million license fee to Fidelion - marketscreener.com
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene - The Manila Times
BioNexus Gene Lab (Nasdaq: BGLC) secures royalty-free VitaGuard MRD rights in SE Asia - Stock Titan
BioNexus Gene Lab Corp Stock Analysis and ForecastMarket Sentiment Shifts & Hedge Fund-Style Analysis Now Free - earlytimes.in
BioNexus Gene Lab Corp. announced that it expects to receive $500 million in funding from ARC Group International Ltd - marketscreener.com
Bionexus Gene Lab Corp (BGLC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.79%
2.16%
자본화:
|
볼륨(24시간):